Morgan Stanley Protagonist Therapeutics, Inc Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Morgan Stanley holds 868,963 shares of PTGX stock, worth $66.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

868,963

Previous 497,105 74.8%

Holding current value

$66.2 Million

Previous $24 Million 99.79%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$40.89 - $56.37 $15.2 Million - $21 Million	371,858 Added 74.8%	868,963 $48 Million
Q1 2025 May 15, 2025	SELL	$35.09 - $59.76 $1.52 Million - $2.58 Million	-43,210 Reduced 8.0%	497,105 $24 Million
Q4 2024 Feb 14, 2025	SELL	$38.51 - $48.43 $3.4 Million - $4.28 Million	-88,308 Reduced 14.05%	540,315 $20.9 Million
Q3 2024 May 14, 2025	BUY	$33.72 - $47.33 $9.55 Million - $13.4 Million	283,330 Added 82.05%	628,623 $28.3 Million
Q3 2024 Nov 14, 2024	BUY	$33.72 - $47.33 $9.55 Million - $13.4 Million	283,330 Added 82.05%	628,623 $28.3 Million
Q2 2024 May 14, 2025	SELL	$24.66 - $34.8 $4.81 Million - $6.79 Million	-195,022 Reduced 36.09%	345,293 $12 Million
Q2 2024 Oct 17, 2024	SELL	$24.66 - $34.8 $37.8 Million - $53.4 Million	-1,534,585 Reduced 81.63%	345,293 $12 Million
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $37.8 Million - $53.4 Million	-1,534,585 Reduced 81.63%	345,293 $12 Million
Q1 2024 Oct 17, 2024	BUY	$21.79 - $32.15 $33.4 Million - $49.3 Million	1,534,585 Added 444.43%	1,879,878 $54.4 Million
Q1 2024 Aug 16, 2024	BUY	$21.79 - $32.15 $15 Million - $22.1 Million	688,041 Added 57.73%	1,879,878 $54.4 Million
Q1 2024 May 15, 2024	BUY	$21.79 - $32.15 $15 Million - $22.1 Million	688,041 Added 57.73%	1,879,878 $54.4 Million
Q4 2023 Aug 16, 2024	BUY	$14.05 - $23.44 $11.9 Million - $19.8 Million	846,544 Added 245.17%	1,191,837 $27.3 Million
Q4 2023 Feb 13, 2024	BUY	$14.05 - $23.44 $10.7 Million - $17.9 Million	762,833 Added 177.81%	1,191,837 $27.3 Million
Q3 2023 Nov 15, 2023	SELL	$16.68 - $23.66 $2.49 Million - $3.53 Million	-149,017 Reduced 25.78%	429,004 $7.16 Million
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $17.9 Million - $29.1 Million	-992,489 Reduced 63.2%	578,021 $16 Million
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $9.36 Million - $22 Million	-868,007 Reduced 35.6%	1,570,510 $36.1 Million
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $1.55 Million - $2.36 Million	210,942 Added 9.47%	2,438,517 $26.6 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $3.55 Million - $5.28 Million	451,123 Added 25.39%	2,227,575 $18.8 Million
Q2 2022 Oct 27, 2022	BUY	$7.06 - $25.52 $3.1 Million - $11.2 Million	439,349 Added 32.86%	1,776,452 $14.1 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $3.1 Million - $11.2 Million	439,349 Added 32.86%	1,776,452 $14.1 Million
Q1 2022 Oct 27, 2022	SELL	$23.34 - $36.08 $10.3 Million - $15.9 Million	-439,349 Reduced 24.73%	1,337,103 $31.7 Million
Q1 2022 May 13, 2022	BUY	$23.34 - $36.08 $28.7 Million - $44.4 Million	1,229,687 Added 1144.79%	1,337,103 $31.7 Million
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $6.47 Million - $13.6 Million	-366,899 Reduced 77.35%	107,416 $3.67 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $6.14 Million - $23.6 Million	474,315 New	474,315 $8.41 Million

Others Institutions Holding PTGX

# of Institutions

296

Shares Held

67.4M

Call Options Held

290K

Put Options Held

318K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $3.74B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account